EUCTR2014-000103-27-NO
Active, not recruiting
Phase 1
Plasma levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept in patients with exudative age-related macular degeneration.
Not provided0 sitesAugust 31, 2016
DrugsEylea
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Not provided
- Status
- Active, not recruiting
- Last Updated
- 9 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with wet AMD
- •Central retinal thickness \> 250 micrometers
- •Best corrected visual acuity 20/25\-20/320
- •Age \> 50 years
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 20
- •F.1\.3 Elderly (\>\=65 years) no
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •Macular edema of other ethiology
- •Bilateral disease
- •Intravitreal anti\-VEGF treatment the last 3 months
- •Intraocular pressure \> 30 mmHg
- •Active inflamation in the eye
- •Systemic steroid or anti\-VEGF treatment
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Serum concentration of vascular endothelial growth factor of patients with chorioretinal diseases before and after the anti-vascular endothelial growth factor therapydiabetic retinopathy, central retinal vein occlusion, branch retinal vein occlusion, age-related macular degeneration, myopic choroidal neovascularization, idiopathic choroidal neovascularizationJPRN-UMIN000009312Department of Ophthalmology, Shiga University of Medical Science100
Recruiting
Not Applicable
VEGF and medicine concentration in serum and eye of patients with age-related macular degeneration before and after anti-VEGF therapyage-related macular degenerationJPRN-UMIN000041817Department of Ophthalmology, Shiga University of Medical Science30
Recruiting
Not Applicable
Plasma concentration of vascular endothelial growth factor in very low birth weight infants at Nagaoka Red Cross hospitalretinopathy of prematurityJPRN-UMIN000027480agaoka Red Cross Hospital50
Completed
Phase 4
Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of AfliberceptExudative Age-related Macular DegenerationNCT02125864Oslo University Hospital16
Recruiting
Not Applicable
Vascular Endothelial Growth Factor, thrombelastography and coagulation in the context of etiology, outcome and clinical course of patients after circulatory arrestI46Cardiac arrestDRKS00033234BG-Klinikum Unfallkrankenhaus Berlin150